Akero Therapeutics, Inc. (AKRO)

NASDAQ: AKRO · IEX Real-Time Price · USD
25.26
+0.81 (3.31%)
At close: Mar 28, 2024, 4:00 PM
25.47
+0.21 (0.83%)
After-hours: Mar 28, 2024, 5:29 PM EDT
3.31%
Market Cap 1.69B
Revenue (ttm) n/a
Net Income (ttm) -151.76M
Shares Out 68.95M
EPS (ttm) -2.89
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 851,489
Open 24.62
Previous Close 24.45
Day's Range 23.71 - 25.43
52-Week Range 11.25 - 58.38
Beta -0.37
Analysts Strong Buy
Price Target 46.29 (+83.25%)
Earnings Date May 13, 2024

About AKRO

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manuf... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 20, 2019
Employees 56
Stock Exchange NASDAQ
Ticker Symbol AKRO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for AKRO stock is "Strong Buy." The 12-month stock price forecast is $46.29, which is an increase of 83.25% from the latest price.

Price Target
$46.29
(83.25% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Akero Therapeutics, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights – AKRO

NEW YORK, NY / ACCESSWIRE / March 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Akero Therapeutics, Inc. ("Akero Therapeutics") (NASDAQ:AKRO) concerning poss...

17 hours ago - Accesswire

Akero Therapeutics, Inc. (AKRO) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates

NEW YORK, NY / ACCESSWIRE / March 27, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Akero Therapeutics, Inc. ("Akero Therapeutics") (NASDAQ:AKRO) concerning poss...

1 day ago - Accesswire

Shareholder Rights Advocates at Levi & Korsinsky Investigate Akero Therapeutics, Inc. (AKRO) Regarding Possible Securities Fraud Violations

NEW YORK, NY / ACCESSWIRE / March 27, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Akero Therapeutics, Inc. ("Akero Therapeutics") (NASDAQ:AKRO) concerning poss...

1 day ago - Accesswire

Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

SOUTH SAN FRANCISCO, Calif., March 08, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metab...

20 days ago - GlobeNewsWire

Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology

As reported previously, the addition of EFX to GLP-1 receptor agonist therapy had a safety and tolerability profile comparable to that of EFX alone and led to statistically significant improvements in...

21 days ago - GlobeNewsWire

Akero Therapeutics Announces Pricing of Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metab...

23 days ago - GlobeNewsWire

Akero Therapeutics Announces Proposed Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metab...

24 days ago - GlobeNewsWire

Akero's lead drug helps improve scarring in fatty liver disease patients

Akero Therapeutics said on Monday its lead experimental drug to treat a type of fatty liver disease helped improve scarring in patients' organ after 96 weeks, meeting the main goal of a mid-stage stud...

25 days ago - Reuters

Akero Therapeutics to Present Topline Week 96 Results from Phase 2b HARMONY Study Investigating Efruxifermin in Patients with Pre-Cirrhotic MASH

Investor webcast on Monday, March 4 at 8:00 a.m. ET to present clinical data Investor webcast on Monday, March 4 at 8:00 a.m. ET to present clinical data

4 weeks ago - GlobeNewsWire

Akero Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabo...

4 weeks ago - GlobeNewsWire

Cramer's Stop Trading: Akero Therapeutics

CNBC's Jim Cramer explains why he is keeping an eye on shares of Akero Therapeutics.

7 weeks ago - CNBC Television

Akero Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabo...

3 months ago - GlobeNewsWire

Akero Therapeutics Announces First Patients Dosed in Efruxifermin Phase 3 SYNCHRONY Program

Week 96 Phase 2b HARMONY Results for Treatment of Patients with Pre-Cirrhotic NASH/MASH (F2-F3) to be Reported in March 2024

3 months ago - GlobeNewsWire

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Akero Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / November 22, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Akero Therape...

4 months ago - Accesswire

Akero Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

-- Phase 3 SYNCHRONY studies actively screening and on track to begin enrolling by the end of 2023 -- SOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: A...

4 months ago - GlobeNewsWire

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Akero Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / November 13, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Akero Therape...

4 months ago - Accesswire

Akero Therapeutics to Present Late-Breaking Oral and Poster Presentations on EFX at AASLD's The Liver Meeting® 2023

Phase 2b SYMMETRY 36-week data, including new subgroup analysis, showed that EFX is active in patients with advanced cirrhosis and support continued development of EFX for treatment of cirrhosis due t...

5 months ago - GlobeNewsWire

Akero Therapeutics to Present at Upcoming Healthcare Conferences in November

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabo...

5 months ago - GlobeNewsWire

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Akero Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / October 19, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Akero Therapeu...

5 months ago - Accesswire

Akero Therapeutics to Present at the H.C. Wainwright 7th Annual NASH Virtual Investor Conference

SOUTH SAN FRANCISCO, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabo...

5 months ago - GlobeNewsWire

Stocks trending October 10, 2023: Akero Therapeutics, Palantir, Hyatt Hotels

Stocks are higher in early trading on dovish commentary from Federal Reserve officials. Hyatt Hotels Corporation (H) shares jump as the company will be replacing National Instruments (NATI) on the S&P...

Other symbols: HPLTR
6 months ago - Yahoo Finance

Akero Therapeutics stock crashed 65% on Tuesday: what happened?

Akero Therapeutics Inc (NASDAQ: AKRO) crashed more than 65% this morning after reporting interim results of SYMMETRY – a Phase 2b study of its non-alcoholic steatohepatitis (NASH) candidate. Akero The...

6 months ago - Invezz

Akero Therapeutics shares plunge on liver disease treatment's mixed results

Akero Therapeutics Inc. shares AKRO, -3.56% fell more than 60% premarket on Tuesday after the company released an update on its lead product candidate, a treatment for nonalcoholic steatohepatitis, a ...

6 months ago - Market Watch

Akero's drug for fatty liver disease misses main trial goal

Akero Therapeutics said on Tuesday a mid-stage trial for its drug to treat a type of fatty liver disease showed improvement in patients, but the results were not statistically significant, sending its...

6 months ago - Reuters